U.S. Markets open in 7 hrs 52 mins

Psykey, Inc. (CEOS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0600-0.0040 (-6.25%)
At close: 03:53PM EDT

Psykey, Inc.

17 Belfield Road
Toronto, ON M9W1E8
888 376 8258

IndustryMedical Instruments & Supplies
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. James J. FiedlerChairman & CEON/AN/A1947
Mr. Robert GardinerPres & DirectorN/AN/AN/A
Sukhinder KalsiCFO & DirectorN/AN/AN/A
Mr. Mark PerkellVP and Gen. CounselN/AN/AN/A
Dr. Allen Greenspoon M.D.VP & DirectorN/AN/A1954
Dr. Jasbir S. Kang M.D.Treasurer, Sec. & DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.

Corporate Governance

Psykey, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.